- Johnson & Johnson plans to separate its Orthopaedics business.
- The new entity will operate as DePuy Synthes.
- The separation aims to focus on high-growth, high-margin markets.
- Johnson & Johnson will retain leadership in six key growth areas.
Separation Announcement
Johnson & Johnson announced its intent to separate its Orthopaedics business to enhance strategic and operational focus. The move aims to drive value for stakeholders by establishing a standalone orthopaedics company.
New Entity: DePuy Synthes
The separated business will operate as DePuy Synthes, becoming the largest orthopaedics-focused company with leading market share positions across major categories.
Strategic Focus
The separation is part of Johnson & Johnson's strategy to focus on high-growth and high-margin markets, particularly in its MedTech portfolio. This aligns with the company's commitment to portfolio optimization and value creation.
Future Growth Areas
Post-separation, Johnson & Johnson will maintain leadership in six key growth areas: Oncology, Immunology, Neuroscience, Cardiovascular, Surgery, and Vision. The company expects the separation to boost top-line growth and operating margins.
